Anti-psoriatic Effect of TL01 Light Therapy
Launched by UNIVERSITY OF ABERDEEN · Nov 4, 2015
Trial Information
Current as of June 08, 2025
Completed
Keywords
ClinConnect Summary
Six patients with plaque psoriasis were recruited from the phototherapy unit. These patients were referred by their dermatologist to receive narrow-band UVB (TL01) light treatment. Two 6 mm lesional skin punch biopsies were taken at baseline and 2 weeks after commencing the light treatment to study the effect of light on innate immune cells involved in psoriasis pathogenesis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female psoriasis patients in whom the decision to treat with NB-UVB therapy, as part of their routine clinical care, has been taken by their dermatologist in the age range of 18-70 years.
- Exclusion Criteria:
- • patients currently on antipsoriatic treatment.
- • Patients with immunosuppressive diseases
- • Patients on immunosuppressive therapies
- • Pregnant or lactating female patients
- • Patients unable to provide a written consentProcedure
About University Of Aberdeen
The University of Aberdeen, a prestigious institution founded in 1495, is a leading center for research and education in healthcare and clinical sciences. With a commitment to advancing knowledge and improving patient outcomes, the university actively sponsors clinical trials that explore innovative treatments and therapies across various medical fields. Leveraging its interdisciplinary expertise and state-of-the-art facilities, the University of Aberdeen fosters collaborations with healthcare professionals and industry partners to enhance the quality of clinical research and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aberdeen, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials